Metabasis Therapeutics 8-K 2009
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 14, 2009
Metabasis Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Registrants telephone number, including area code: (858) 587-2770
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
(b) Due to the discontinuation of our research and development activities, we discontinued Barry Gumbiner, M.D.s employment as our Vice President of Clinical Development and Chief Medical Officer, effective October 14, 2009. Following his departure, Dr. Gumbiner will continue to consult with us on matters related to the licensing or sale of our pipeline of product candidates and advanced discovery programs or other strategic alternatives.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 20, 2009